TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06584421: KYSA-6: Phase 2/3 Registrational Trial of KYV-101 Autologous Anti-CD19 CAR-T Cell Therapy in Generalized Myasthenia Gravis

Sponsor: Kyverna Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 96 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$20,105,600

Rescue Site Savings

+$13,257,130

Unlock Full NCT06584421 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06584421 Rescue Dossier →